Tamtam Try Tamtam free
Medpace logo

Medpace account plan

Clinical research services

At a glance

Medpace: Cincinnati full-service clinical CRO for Phase I-IV trials, $2,530.2 million FY2025 revenue and about 6,600 employees in 46 countries.

Medpace Holdings, Inc. is a Cincinnati-based, full-service clinical contract research organization running Phase I-IV trials for biotechnology, pharmaceutical and medical device companies, and positions itself as a partner of choice for small and mid-sized biopharmaceutical companies. Its integrated offering spans medical leadership, trial management on its proprietary ClinTrak system, monitoring, regulatory affairs, biometrics, central and bioanalytical laboratories and Phase I clinics. FY2025 revenue was $2,530.2 million (+20.0%) and net income $451.1 million. It had about 6,600 employees across 46 countries at 30 September 2026, carries no debt and is listed on Nasdaq; founder August J. Troendle controls about 19.0% of the shares.

Business units

Strategic priorities

Grow Phase I-IV market share
Expand mainly organically through the full-service model and therapeutic depth, with only "potentially highly selective bolt-on acquisitions and investments".
Win rate and awards
Process changes made late in 2025 to raise the win rate; net new business awards reached $873.4 million in Q3 2026 (+10.6%) and trailing 12-month awards grew 23.9%.
Small and mid-sized biotech focus
Large pharma "is not a focus"; purely functional (FSP) outsourcing is declined in favour of full-service projects.
Hiring and retention
Hiring growth in the mid to high single digits in 2026, with margin gains from retention and utilization rather than restructuring; headcount rose from about 6,200 to about 6,600 in nine months.
Capital return
A new buyback authorization of up to $1.0 billion until 31 December 2028, after $912.9 million of repurchases in 2025.

Latest results

In Q3 2026 revenue rose 8.5% to $716.0 million and GAAP net income to $137.5 million ($4.84 per diluted share), with EBITDA up 16.0% to $172.1 million (24.0% margin). Nine-month revenue was $2,129.9 million (+16.9%). Backlog reached $3,167.2 million (+5.6%), with $1,980.0-2,000.0 million expected to convert over the next twelve months. 2026 guidance is revenue of $2.835-2.855 billion (+12.0% to 12.8%), GAAP net income of $514.0-524.0 million and EBITDA of $638.0-652.0 million; 2027 guidance comes in February.

Investments and deals

Cincinnati campus expansion
A significant expansion of the Cincinnati campus will add about $20 million of operating costs in 2027; capital spending rose to 2.39% of revenue over nine months of 2026.
Share repurchases
2,961,924 shares bought for $912.9 million in 2025 and 705,616 shares for $294.7 million in 2026; a new authorization of up to $1.0 billion was approved effective 20 October 2026.
AI adoption
First AI uses target efficiency across the organisation and data analytics for feasibility and site selection; management expects the investment to at least equal the benefits in 2026.

Challenges and risks

Contract cancellations
Q4 2025 backlog cancellations were the highest in over a year, and Q3 2026 cancellations were toward the higher end of the expected range, now driven mainly by product failure and safety signals.
Customer and therapeutic concentration
Top 5 and top 10 customers were roughly 31% and 39% of trailing 12-month revenue; several trials in one therapeutic class can be cancelled together.
AI disruption
The CEO calls AI, on the surface, a net negative for a service company paid to provide staff over a period of years; the 10-K also flags a competitive risk from under-investing in AI tools.
Client acquisitions by large pharma
When large pharma buys a biotech client, Medpace generally keeps the work but loses the client long term.

What leadership says

“The business environment remains strong”

August J. Troendle, Chairman and Chief Executive Officer · Q3 2026 earnings call, 22 October 2026

“Cancellations were elevated again in Q4. Backlog cancellations in absolute and percent terms were the highest they've been in over a year.”

August J. Troendle, Chairman and Chief Executive Officer · Q4 and full year 2025 earnings call, 10 February 2026

“some of the crazy approaches taken by some in the past few years have died out. I think we are kind of back to a normalized environment”

August J. Troendle, Chairman and Chief Executive Officer · Q3 2026 earnings call, 22 October 2026, on pricing

Where a supplier can help

Site selection and feasibility analytics
Tied to AI adoption, whose first uses include data analytics for feasibility and site selection: data and analytics providers for trial planning.
Training and talent tools
Tied to the hiring and retention priority: learning, recruiting and retention tools for a company that hires ahead and trains its own staff.
Campus build-out and laboratory equipment
Tied to the Cincinnati campus expansion: facilities, fit-out and laboratory suppliers.
Patient recruitment
Tied to the challenge of cancellations and the 10-K risk on investigator and patient recruitment: recruitment and retention services that keep studies on track.
Biotech pipeline intelligence
Tied to the small and mid-sized biotech focus and the win-rate priority: market intelligence that helps business development find funded sponsors.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Medpace?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Medpace

What does Medpace do?

Medpace is a full-service clinical contract research organization that runs Phase I-IV trials for biotechnology, pharmaceutical and medical device companies, mainly small and mid-sized biopharma.

What is Medpace's revenue?

FY2025 revenue was $2,530.2 million, up 20.0%. For 2026 Medpace guides to $2.835-2.855 billion.

How many employees does Medpace have?

About 6,600 employees across 46 countries as of 30 September 2026, up from about 6,200 at the end of 2025.

Who leads Medpace?

Founder August J. Troendle is Chief Executive Officer, President and Chairman; Kevin M. Brady is Chief Financial Officer.

Which therapeutic areas matter most to Medpace?

Oncology and Metabolic each brought about 29% of FY2025 revenue, followed by Other areas, CNS, Cardiology and AVAI.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)